Investors Alert: Pomerantz Law Firm Launches Class Action Against Immutep Limited

Investors Alert: Class Action Lawsuit Against Immutep Limited

On May 7, 2026, the renowned law firm Pomerantz LLP announced that it has filed a class action lawsuit against Immutep Limited (NASDAQ: IMMP). This lawsuit addresses potential securities fraud and other unlawful practices allegedly engaged in by Immutep and certain officers or directors of the company.

Affected investors who have suffered losses during the relevant investment period are strongly encouraged to come forward. Danielle Peyton from Pomerantz is the contact for further inquiries, and those interested in joining the lawsuit should reach her at [email protected] or by calling 646-581-9980 or toll-free at Ext. 7980. When contacting, it is advisable to include personal details such as mailing address, phone number, and the number of shares purchased.

Background of the Case

The class action lawsuit stems from serious allegations surrounding the conduct of Immutep and its management team. These accusations relate to the issuance of false and misleading information to investors, leading to significant financial losses when the truth was revealed.

One of the critical moments was on March 13, 2026, when the Independent Data Monitoring Committee (IDMC) recommended the discontinuation of a Phase III study (TACTI-004) evaluating Immutep's drug, eftilagimod alfa ('efti'), for treating first-line non-small cell lung cancer. The study was halted following a planned interim futility analysis, concluding that the data did not support further progression. Consequently, the company announced that enrollment would cease and that an orderly wind-down process would be implemented.

This resulted in a drastic drop in Immutep's American Depositary Receipt (ADR) price, which fell to $0.48—representing a staggering 82.44% drop in value, as reported after the announcement. This significant loss has led numerous investors to seek legal recourse through this class action.

Important Deadlines

Investors who have purchased Immutep securities during the class period have until July 6, 2026, to apply to the Court to be appointed as Lead Plaintiff. Those interested in reviewing the Complaints can access them via Pomerantz's website.

Pomerantz LLP has a proven track record in corporate, securities, and antitrust class litigation. Established by Abraham L. Pomerantz, often referred to as the dean of the class action bar, the firm has over 85 years of experience advocating for the rights of investors. Their dedication is clear, as they have successfully recovered numerous multi-million dollar damages awards on behalf of their clients.

Conclusion

For investors facing potential losses due to their involvement with Immutep, taking action is critical. Pomerantz’s class action lawsuit offers a path to seek compensation. As the legal proceedings unfold, impacted investors should stay informed and consider joining the action before the looming deadline.

Inquiries can be directed to Pomerantz LLP for assistance. Stand up for your rights as an investor and ensure that all necessary steps are taken to safeguard your interests.

For further information or updates, stay connected through Pomerantz’s communications or consult with legal advisors familiar with securities litigation.